<DOC>
	<DOCNO>NCT02173873</DOCNO>
	<brief_summary>Aflibercept FDA approve molecule available hyperosmolar oncology ( cost 800 USD 4ml ) isoosmolar Ophthalmology ( cost 1,770 USD 0.05ml injection ) . The 4ml bottle fractionate used 40 patient hence 0.05 ml injection would cost 20 USD patient . Animal study show injection safe , know rabbit vitreous volume 3-4 time small human eye . Our pilot study ascertain approve molecule oncology inject eye safe dilute 5ml vitreous ( 100 time dilution ) . If save patient 100 time efficient antiVEGF use maculopathy various disease ( AMD , DME , CRVO , etc.. )</brief_summary>
	<brief_title>Ziv-aflibercept Eyes With Retinal Diseases Poor Vision-phase I</brief_title>
	<detailed_description>Protocol Inject 0.05 ml zaltrap coumpounded sterile way vitreous blind eye ( vision less 20/100 ) various disease retina require antiVEGF therapy patient consent . Vision monitor 15 minute , 1 day 1 week injection . SD-OCT perform 1 week look possible side effect . The safety efficacy Eylea treatment macular edema follow CRVO3,4 assess 2 randomize , multicenter , double-masked , sham-controlled study : COPERNICUS GALILEO . A total 358 patient treat evaluable efficacy ( 217 Eylea ) two study . In , patient randomly assign 3:2 ratio either 2 mg Eylea administer every 4 week , sham injection ( control group ) administer every 4 week total 6 injection . After 6 monthly injection , patient continue receive Eylea treatment week 24 52 meet pre-specified retreatment criterion ( PRN ) , except patient sham control group GALILEO study continue receive sham injection week 52 . In COPERNICUS study , 6 month , 56 % patient receive Eylea 2 mg monthly gain least 15 letter BCVA baseline , measure ETDRS , compare 12 % patient receive sham injection ( p &lt; 0.01 ) , primary endpoint study . Patients receive Eylea 2 mg monthly gain , average , 17.3 letter vision compare mean loss 4.0 letter sham control injection ( p &lt; 0.01 ) , secondary endpoint . Ziv-aflibercept zaltrap6 ( Sanofi-Aventis US , LLC , Bridgewater , NJ/Regeneron Pharmaceuticals , Inc , Tarrytown , NY ) FDA approve treatment metastatic colorectal cancer . During Bascom Palmer Eye Institute 's Angiogenesis , Exudation , Degeneration February 2014 conference , Michel Eid Farah , Jo√£o R. Dias , Fernando M. Penha , Eduardo B. Rodrigues investigate safety ziv-aflibercept vitro vivo . In vitro toxicity verify use ARPE-19 culture cell expose anti-angiogenic v balance salt solution ( BSS ) 10 minute . Viability assess 3- ( 4,5-dimethylthiazol-2-yl ) -2,5-diphenyltetrazolium bromide ( MTT ) assay , evaluate cell viability mitochondrial activity . No sign cell toxicity observe , cell viability similar ziv-aflibercept , aflibercept , BSS . For vivo study , test 1 injection 0.05 mL ziv-aflibercept v aflibercept right eye 18 rabbit , 9 eye group . BSS inject fellow eye serve control . After injection , animal examine funduscopy , SD-OCT ) , ERG baseline , 24 hour , 7 day . Aqueous , vitreous , serum sample collect baseline , 24 hour , 7 day pH osmolarity analysis . The animal sacrifice eye enucleate morphologic study light electron microscopy . No abnormality find 24 hour 7 day intravitreal injection either drug assess fundus exam SD-OCT , ERG , histology well transmission microscopy . There also change osmolarity aqueous humor vitreous sample group 24 hour 1 week .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Retinal Diseases</mesh_term>
	<criteria>Eyes wet age relate macular degeneration , central retinal vein occlusion diseases require antiVEGF especially poor vision eye eye recent eye surgery , inability sign consent , blepharitis , conjunctivitis</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Age relate macular degeneration</keyword>
	<keyword>central retinal vein occlusion</keyword>
</DOC>